HOME >> MEDICINE >> NEWS
AstraZeneca announces SYMBICORT is now available in the US

Wilmington, Del. June 25, 2007 -- AstraZeneca announced today that SYMBICORT (budesonide/formoterol fumarate dihydrate) pressurized metered dose inhaler (pMDI) is now available in the United States for the long-term maintenance treatment of asthma in patients 12 years of age and older.

Administered twice daily, SYMBICORT is a combination of two proven asthma medications budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long-acting beta2-agonist (LABA). For many patients, this combination treatment offers improved asthma control as early as day one that is sustained over 12 weeks. SYMBICORT also delivers improved lung function occurring within 15 minutes of beginning treatment. SYMBICORT does not replace fast-acting inhalers for sudden attacks.

SYMBICORT is available in two dose strengths, 80/4.5 and 160/4.5 mcg of budesonide and formoterol, respectively. SYMBICORT is approved for patients whose disease is not adequately controlled on another asthma-controller medication (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies.

With the U.S. launch of SYMBICORT, millions of asthma sufferers will have a new choice of fixed combination therapy to help achieve control of their asthma, said Chris OBrien, MD, PhD, senior director, Medical Science, AstraZeneca.

Asthma is one of the most serious chronic diseases in the U.S. It is estimated that more than 20 million Americans suffer from the condition and, if not properly managed, asthma can be life-threatening.

The U.S. availability of SYMBICORT holds great promise for millions of Americans that suffer from asthma, said Tony Zook, president and chief executive officer, AstraZeneca U.S. The addition of SYMBICORT to our respiratory portfolio reinforces AstraZenecas commitment to developing new, effective treatments, and provides patients and physicians
'"/>

Contact: Tracy Knudsen
Tracy.Knudsen@astrazeneca.com
302-885-1933
AstraZeneca
25-Jun-2007


Page: 1 2

Related medicine news :

1. AstraZeneca, University of Miami, and Humana collaborate to improve consumer health
2. AstraZeneca and M. D. Anderson Cancer Center form umbrella scientific collaboration agreements
3. W.M. Keck Foundation announces 2007 class of Distinguished Young Scholars in medical research
4. Weill Cornell Medical College announces gifts totaling $400M
5. GSK announces launch of largest ever Phase III trial in lung cancer treatment
6. Elsevier announces launch of Brain Stimulation
7. NSW Premier announces $15M for childrens cancer research
8. National Inventors Hall of Fame announces 2007 inductees
9. Emory University announces new Global Health Institute
10. BioMed Central announces Journal of Medical Case Reports
11. Tibotec Therapeutics announces start of largest US study on HIV treatment in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2019)... ... February 19, 2019 , ... ... stigma in pregnant and postpartum women, a team led by a Worcester Polytechnic ... postpartum often show increased depressive symptoms, greater weight gain during pregnancy, and weight ...
(Date:2/19/2019)... ... February 19, 2019 , ... Landscape Structures Inc., a Delano, Minn.-based commercial ... to be a stunning and fun addition to any play space. Spinning is one ... Curva™ Spinners will provide kids’ brains with valuable equilibrium information. , Whether park and ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... experience to The Oncology Institute of Hope and Innovation. , Dr. Lombardi completed ... cum laude. He received his medical degree from the University of Rochester School ...
(Date:2/19/2019)... ... February 19, 2019 , ... ClearHealth ... to Foley & Lardner LLP, as Recognized Consultants. The CHQI Recognized Consultant Program ... in pursuing CHQI accreditation. , Ms. Wein and Mr. Einhorn are part ...
(Date:2/19/2019)... Fla. (PRWEB) , ... February 18, 2019 , ... ... in the nation to test the PathO3Gen Solutions Footwear Sanitizing Stations to maximize ... Solestice 3/15 TechnologyTM to kill superbugs such as MRSA and C. difficile, which ...
Breaking Medicine News(10 mins):
(Date:2/19/2019)... (PRWEB) , ... February 19, ... ... and infrastructure solutions provider for global service providers, enterprises, and developers, announced ... orchestration platform with the Arvizio MR Studio mixed reality visualization and collaboration ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... for Stage IV metastatic breast cancer (MBC), announces the opening of the 2019 ... Fairchild, “In honor of our 10-year anniversary, we are excited to announce we ...
(Date:2/19/2019)... ... February 19, 2019 , ... ... completed his new book “Live Hard Die Young.” Dr. Oexner was the first ... medicine, therapeutic exercise physiology, and nutritional counseling. Dr. Oexner was a supervisor on ...
Breaking Medicine Technology:
Cached News: